Please check your internet connection and try again.
# Tradjenta (linagliptin)
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing incretin levels, which helps to suppress glucagon release and increase insulin secretion in a glucose-dependent manner.
## Primary Indications
* Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
* Can be used as monotherapy or in combination with metformin, sulfonylureas, thiazolidinediones, or insulin.
## Adult Dosing
* **Recommended Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg once daily.
## Pediatric Dosing
Dosing has not been established in pediatric patients.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is required regardless of the degree of renal impairment.
* **Hepatic Impairment:** No dose adjustment is required in patients with hepatic impairment.
## Contraindications
* Known serious hypersensitivity to linagliptin or any excipients in the formulation.
## Adverse Effects
* **Common:** Nasopharyngitis, upper respiratory tract infection.
* **Serious:** Hypersensitivity reactions (including anaphylaxis, angioedema, urticaria, rash), bullous pemphigoid, severe and disabling arthralgia (joint pain), hypoglycemia (especially when used with a sulfonylurea or insulin).
## Key Drug Interactions
* **DPP-4 Inhibitors:** Use with other DPP-4 inhibitors is not recommended.
* **CYP3A4 Inducers:** Strong inducers of CYP3A4 (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital) may decrease linagliptin exposure and efficacy. Monitor glycemic control closely if coadministered.
## Monitoring
* **Blood Glucose:** Monitor blood glucose levels to assess efficacy and guide therapy adjustments.
* **Renal Function:** Routine monitoring is not required, but consider in the context of overall patient care.
* **Signs of Hypersensitivity:** Educate patients on the signs and symptoms of hypersensitivity reactions.
* **Joint Pain:** Monitor for signs of severe and disabling arthralgia.
## Clinical Pearls
* Linagliptin does not require dose adjustment for renal or hepatic impairment, making it a convenient option for patients with these comorbidities.
* Due to its excretion primarily via the bile and subsequent intestinal excretion, it does not accumulate in patients with renal impairment.
* Be aware of the risk of hypoglycemia when coadministered with insulin or sulfonylureas.
* Educate patients on the potential for rare but serious hypersensitivity reactions and severe joint pain.
***
**Disclaimer:** This information is intended for clinical professionals and is not a substitute for comprehensive prescribing information. Always consult the most current product labeling and relevant clinical guidelines before making treatment decisions.
